Navigation Links
Advanced Targeting Systems, Inc. Announces $3 Million Award from National Cancer Institute
Date:9/23/2010

SAN DIEGO, Sept. 23 /PRNewswire/ -- Advanced Targeting Systems, the company that pioneered the targeting of specific cell types to manipulate them for the treatment of diseases and for research into the function of biological systems, has been awarded $3 million from the National Cancer Institute (NCI). Representatives from the NCI stated that the proposal was ranked #1 for funding out of a nationwide program with hundreds of applicants. Advanced Targeting Systems will use the funds to advance its patented drug, SP-SAP, over the next two years to initiate clinical trials for cancer pain.

SP-SAP is a conjugate between the pain-processing peptide Substance P and the ribosome-inactivating protein saporin. The mechanism of action of SP-SAP is well characterized, a rarity in pain therapeutics: a small number of cells that process pathological pain signals is removed, causing relief that appears to be permanent. Normal acute pain is unaffected.

The Food and Drug Administration has recommended that the first population to undergo treatment with SP-SAP is terminal cancer patients who are resistant to opioids such as morphine. Pain due to cancer is a great fear, at times greater than even the fear of death, in the progression of the disease. To make matters worse, many times this pain is unresponsive to the last-stand treatment: opioids. There is also a common fear among terminal patients that current pain treatments will leave them unable to function normally at a time when it is personally extremely important for them. In preclinical tests, a single treatment with SP-SAP alleviated pathologic pain perception without affecting other sensory signal pathways.

Advanced Targeting Systems assembled a team of experts for this project, including: Dr. Art Frankel, leading expert on the use of targeted toxins in cancer (Scott & White Cancer Research Center); Dr. Allen Burton, author of over 60 publications on cancer pain (MD Anderson Cancer Center, Pain Medicine: sees over 10,000 cancer-related pain patients each year); and Dr. Dorothy Brown, toxicology consultant who led veterinary cancer pain studies in dogs with osteosarcoma (University of Pennsylvania). All regulatory aspects of the project will be spearheaded by the professional team at Cato Research, a full-service CRO with over 20 years of experience in drug development services, including CMC, clinical and regulatory strategies, as well as clinical trial support.  

"I am gratified that the National Cancer Institute and the peer reviewers recognize the strength and quality of the 'Dream Team' of physicians, researchers and regulatory specialists that we have put together for this project," stated Dr. Douglas Lappi, Principal Investigator and President/CSO of Advanced Targeting Systems.

The BRDG-SPAN program is supported by funds provided to the NIH under the American Recovery & Reinvestment Act of 2009, a component of the Federal Stimulus Package.

For more information, contact Denise Higgins, Vice President, Advanced Targeting Systems. Visit http://www.ATSbio.com for contact information.

This press release was issued through eReleases(R).  For more information, visit eReleases Press Release Distribution at http://www.ereleases.com.


'/>"/>
SOURCE Advanced Targeting Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Aeterna Zentaris Announces NIH Grant for a Phase 1/2 Study in Advanced Prostate Cancer with AEZS-108
2. Elusys Awarded Additional $40.6 Million Under Existing U.S. Government Contract to Fund Advanced Development of Anthim, a New Treatment for Anthrax
3. Advanced Life Sciences Expands Antibiotic Pipeline
4. Advanced Life Sciences CEO Acquires $2 Million of Common Stock Through Debt for Equity Exchange
5. Reportlinker Adds Bioinformatics Market - Advanced Technologies, Global Forecast and Winning Imperatives (2009 - 2014)
6. Aegera Therapeutics Reports Survival Data from the Phase 1 Portion of its Phase 1-2 Study of AEG35156 in Combination with Sorafenib in Patients with Advanced Hepatocellular Carcinoma
7. Sermo Announces New Client Center with Advanced Mining and Monitoring of Organic Physician Dialog
8. Advanced Life Sciences Announces Successful Preclinical Data Supporting Restanza Intravenous Formulation for Hospital Use
9. Advanced Phase I and Phase II Studies of Targeted Gene Delivery Confirm That Rexin-G Impacts Survival in Chemotherapy-resistant Bone and Soft Tissue Sarcoma (ASCO 2010)
10. Onyx Pharmaceuticals Initiates Phase 1 Study of Oral Proteasome Inhibitor in Advanced Solid Tumors
11. NeoStems Advanced Adult Stem Cell Technology to be Featured at Upcoming Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , Oct. ... Cancer Research, London (ICR) and University ... SKY92, SkylineDx,s prognostic tool to risk-stratify patients with multiple myeloma ... MUK nine . The University of Leeds ... partly funded by Myeloma UK, and ICR will perform the ...
(Date:10/10/2017)... ... 2017 , ... San Diego-based team building and cooking events company, Lajollacooks4u, has ... The bold new look is part of a transformation to increase awareness, appeal to ... period. , It will also expand its service offering from its signature gourmet cooking ...
(Date:10/10/2017)... 10, 2017 International research firm Parks Associates announced ... at the TMA 2017 Annual Meeting , October 11 in ... residential home security market and how smart safety and security products impact ... Parks Associates: Smart Home ... "The residential security market has ...
(Date:10/9/2017)... DIEGO , Oct. 9, 2017  BioTech ... biological mechanism by which its ProCell stem cell ... critical limb ischemia.  The Company, demonstrated that treatment ... amount of limbs saved as compared to standard ... the molecule HGF resulted in reduction of therapeutic ...
Breaking Biology Technology:
(Date:3/28/2017)... , March 28, 2017 The ... Hardware (Camera, Monitors, Servers, Storage Devices), Software (Video Analytics, ... Region - Global Forecast to 2022", published by MarketsandMarkets, ... 2016 and is projected to reach USD 75.64 Billion ... and 2022. The base year considered for the study ...
(Date:3/24/2017)... 24, 2017 The Controller General of Immigration from ... Abdulla Algeen have received the prestigious international IAIR Award for the ... Continue Reading ... ... Controller Abdulla Algeen (small picture on the right) have received the IAIR ...
(Date:3/23/2017)... The report "Gesture Recognition and Touchless Sensing Market by Technology (Touch-based ... to 2022", published by MarketsandMarkets, the market is expected to be worth USD ... 2022. Continue Reading ... ... ...
Breaking Biology News(10 mins):